Search Results - "Shevrin, D"

The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer by Xu, W, Neill, T, Yang, Y, Hu, Z, Cleveland, E, Wu, Y, Hutten, R, Xiao, X, Stock, S R, Shevrin, D, Kaul, K, Brendler, C, Iozzo, R V, Seth, P

“…In an effort to develop a new therapy for prostate cancer (PCa) bone metastases, we have created Ad.dcn, a recombinant oncolytic adenovirus carrying the human…”
Get full text

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium Department of Defense Prostate Cancer Clinical Trials Consortium study by Ward, J E, Karrison, T, Chatta, G, Hussain, M, Shevrin, D, Szmulewitz, R Z, O'Donnell, P H, Stadler, W M, Posadas, E M

“…Background: Intermittent androgen suppression (IAS) is an increasingly popular treatment option for castrate-sensitive prostate cancer. On the basis of…”
Get full text

7014 POSTER DISCUSSION Evaluation of Circulating Tumour Cells (CTCs) in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Receiving TAK-700, an Investigational 17,20-lyase Inhibitor by Gross, M, Shevrin, D, Dreicer, R, Trepicchio, W.L, MacLean, D, Webb, I, Wang, J, Agus, D.B

Get full text

Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors by KUKREJA, S. C, SHEVRIN, D. H, WIMBISCUS, S. A, EBELING, P. R, DANKS, J. A, RODDA, C. P, WOOD, W. I, MARTIN, T. J

“…A parathyroid hormone-related protein (PTHrP) has recently been isolated from tumors associated with hypercalcemia. In the present study, we tested the effects…”
Get full text

LBA63 PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19) by Aggarwal, R., Heller, G., Hillman, D., Xiao, H., Picus, J., Wang, J., Taplin, M.E., Dorff, T., Appleman, L.J., Weckstein, D., Patnaik, A., Bryce, A.H., Shevrin, D., Mohler, J., Anderson, D., Rao, A., Tagawa, S.T., Tan, A., Eggener, S., Morris, M.J.

Get full text

Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study by Bancroft, Elizabeth K, Page, Elizabeth C, Castro, Elena, Lilja, Hans, Vickers, Andrew, Sjoberg, Daniel, Assel, Melissa, Foster, Christopher S, Drew, Kate, Mæhle, Lovise, Axcrona, Karol, Evans, D. Gareth, Bulman, Barbara, Eccles, Diana, van Asperen, Christi, Vasen, Hans, Kiemeney, Lambertus A, Ringelberg, Janneke, Cybulski, Cezary, Wokolorczyk, Dominika, Selkirk, Christina, Hulick, Peter J, Bojesen, Anders, Skytte, Anne-Bine, Lam, Jimmy, Taylor, Louise, Oldenburg, Rogier, Verhaegh, Gerald, van Zelst-Stams, Wendy A, Oosterwijk, Jan C, Blanco, Ignacio, Salinas, Monica, Cook, Jackie, Rosario, Derek J, Buys, Saundra, Conner, Tom, Ausems, Margreet G, Ong, Kai-ren, Hoffman, Jonathan, Domchek, Susan, Teixeira, Manuel R, Maia, Sofia, Foulkes, William D, Taherian, Nassim, Ruijs, Marielle, den Enden, Apollonia T. Helderman-van, Izatt, Louise, Davidson, Rosemarie, Adank, Muriel A, Walker, Lisa, Schmutzler, Rita, Tucker, Kathy, Kirk, Judy, Hodgson, Shirley, Harris, Marion, Douglas, Fiona, Lindeman, Geoffrey J, Zgajnar, Janez, Tischkowitz, Marc, Susman, Rachel, Ramón y Cajal, Teresa, Patcher, Nicholas, Spigelman, Allan, Liljegren, Annelie, Side, Lucy, Brewer, Carole, Donaldson, Alan, Stefansdottir, Vigdis, Chen-Shtoyerman, Rakefet, Amor, David J, Barwell, Julian, Giri, Veda N, Murthy, Vedang, Nicolai, Nicola, Teo, Soo-Hwang, Greenhalgh, Lynn, Strom, Sara, Henderson, Alex, McGrath, John, Gallagher, David, Aaronson, Neil, Ardern-Jones, Audrey, Bangma, Chris, Dearnaley, David, Eyfjord, Jorunn, Rothwell, Jeanette, Falconer, Alison, Gronberg, Henrik, Johannsson, Oskar, Kote-Jarai, Zsofia, Axcrona, Ulrika, Melia, Jane, McKinley, Joanne, Mitra, Anita V, Moynihan, Clare, Rennert, Gad, Suri, Mohnish, Wilson, Penny, Killick, Emma, Moss, Sue

“…Abstract Background Men with germline breast cancer 1, early onset ( BRCA1 ) or breast cancer 2, early onset ( BRCA2 ) gene mutations have a higher risk of…”
Get full text

Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial by Sweeney, C., Chen, Y.-H., Liu, G., Carducci, M., Jarrard, D., Eisenberger, M., Wong, Y.-N., Patrick-Miller, L., Hahn, N., Kohli, M., Conney, M., Dreicer, R., Vogelzang, N.J., Picus, J., Shevrin, D., Hussain, M., Garcia, J., Dipaola, R.

Get full text

Assessment of coagulation system activation using spot urine measurements by Lind, S E, Goldshteyn, S, Barry, C P, Lindquist, J R, Piergies, A A, Rosen, T, Schneider, J R, Shevrin, D H, Caprini, J A

“…Coagulation system activation is most commonly assessed by measuring levels of one or more proteins in peripheral blood. Because faulty blood-drawing can cause…”
Get more information

Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death by Na, R, Zheng, S.L, Han, M, Yu, H, Jiang, D, Shah, S, Ewing, C, Zhang, L, Novakovic, K, Petkewicz, J, Gulukota, K, Helseth, D, Quinn, M, Humphries, E, Wiley, K, Isaacs, S, Wu, Y, Liu, X, Zhang, N, Wang, C.-H, Khandekar, J, Hulick, P, Shevrin, D, Cooney, K, Shen, Z, Partin, A, Carter, H.B, Carducci, M, Eisenberger, M, Denmeade, S, McGuire, M, Walsh, P, Helfand, B, Brendler, C, Ding, Q, Xu, J, Isaacs, W

Get full text

Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: An eastern cooperative oncology group study (PB586) by KUCUK, O, SHEVRIN, D. H, PANDYA, K. J, BONOMI, P. D

“…Advanced non-small-cell lung cancer (NSCLC) remains an incurable disease despite significant progress in chemotherapy. We conducted a phase II clinical trial…”
Get full text

Tumor resection and antibodies to parathyroid hormone-related protein cause similar changes on bone histomorphometry in hypercalcemia of cancer by Kukreja, S C, Rosol, T J, Wimbiscus, S A, Shevrin, D H, Grill, V, Barengolts, E I, Martin, T J

“…Bone resorption is increased in both humoral hypercalcemia of malignancy (HHM) and primary hyperparathyroidism. On the other hand, bone formation parameters…”
Get more information

Analysis of Gene Amplification in Human Tumor Cell Lines by Fukumoto, Manabu, Shevrin, Daniel H., Roninson, Igor B.

“…Oncogene amplification has been observed in various primary tumors and tumor-derived cell lines. In several types of cancer, amplification of specific…”
Get full text

Use of clonidine to treat hot flashes secondary to leuprolide or goserelin by Bressler, L R, Murphy, C M, Shevrin, D H, Warren, R F

“…To determine the effects of clonidine, a centrally acting adrenergic agonist, in abating symptoms of hot flashes in men receiving either leuprolide or…”
Get more information

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations by Bancroft, Elizabeth K., Saya, Sibel, Page, Elizabeth C., Myhill, Kathryn, Thomas, Sarah, Pope, Jennifer, Chamberlain, Anthony, Hart, Rachel, Glover, Wayne, Cook, Jackie, Rosario, Derek J., Helfand, Brian T., Hutten Selkirk, Christina, Davidson, Rosemarie, Longmuir, Mark, Eccles, Diana M., Gadea, Neus, Brewer, Carole, Barwell, Julian, Salinas, Monica, Greenhalgh, Lynn, Tischkowitz, Marc, Henderson, Alex, Evans, David Gareth, Buys, Saundra S., Eeles, Rosalind A., Aaronson, Neil K.

“…Objectives To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi‐national investigation of targeted…”
Get full text

Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice by Shevrin, D H, Gorny, K I, Kukreja, S C

“…Cells from the PC-3 human prostate cancer cell line were evaluated in athymic nude mice in order to determine the influence of size of the primary tumor and…”
Get more information

Safety of Radium-223 Dichloride (Ra) with Docetaxel (D) in Patients (Pts) with Bone Metastases (Mets) from Castration-Resistant Prostate Cancer (Crpc): a Phase 1/2A Clinical Trial by Morris, M.J., Higano, C., Scher, H.I., Sweeney, C., Antonarakis, E.S., Shevrin, D., Ryan, C.J., Loriot, Y., Fizazi, K., Pandit-Taskar, N., Garcia-Vargas, J.E., Lyseng, K., Bloma, M., Aksnes, A., Carrasquillo, J.A.

Get full text

756OCHEMOHORMONAL THERAPY VERSUS HORMONAL THERAPY FOR HORMONE NAïVE HIGH VOLUME NEWLY METASTATIC PROSTATE CANCER (PRCA): ECOG LED PHASE III RANDOMIZED TRIAL by Sweeney, C., Chen, Y., Carducci, M., Liu, G., Jarrard, D., Eisenberger, M., Wong, Y., Hahn, N.M., Kohli, M., Vogelzang, N., Cooney, M., Dreicer, R., Picus, J., Shevrin, D., Hussain, M., Garcia, J., Dipaola, R.

“…Abstract Aim: Androgen deprivation therapy (ADT) is standard therapy for metastatic PrCa and although most respond, many develop castration resistant prostate…”
Get full text

765PDSAFETY OF RADIUM-223 DICHLORIDE (RA) WITH DOCETAXEL (D) IN PATIENTS (PTS) WITH BONE METASTASES (METS) FROM CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A PHASE 1/2A CLINICAL TRIAL by Morris, M.J., Higano, C., Scher, H.I., Sweeney, C., Antonarakis, E.S., Shevrin, D., Ryan, C.J., Loriot, Y., Fizazi, K., Pandit-Taskar, N., Garcia-Vargas, J.E., Lyseng, K., Bloma, M., Aksnes, A., Carrasquillo, J.A.

“…Abstract Aim: Ra is an approved α-emitter that prolongs survival in pts with CRPC and symptomatic bone mets (Parker et al. NEJM. 2013). D is an approved…”
Get full text

Chemohormonal Therapy Versus Hormonal Therapy for Hormone Naïve High Volume Newly Metastatic Prostate Cancer (Prca): Ecog Led Phase III Randomized Trial by Sweeney, C., Chen, Y., Carducci, M., Liu, G., Jarrard, D., Eisenberger, M., Wong, Y., Hahn, N.M., Kohli, M., Vogelzang, N., Cooney, M., Dreicer, R., Picus, J., Shevrin, D., Hussain, M., Garcia, J., Dipaola, R.

Get full text

Development of skeletal metastasis by human prostate cancer in athymic nude mice by Shevrin, Daniel H., Kukreja, Subhash C., Ghosh, Luna, Lad, Thomas E.

Get full text